Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivani MedicalVANI -2.59%33 Pretax Margin % is % as of Jun. 2026. GuruFocus rates VANI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 948 Biotechnology companies, Vivani Medical ranks worse than 105485.13% on this metric.
The historical rank and industry rank for Vivani Medical's Pretax Margin % or its related term are showing as below:
VANI's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -76.15 * Ranked among companies with meaningful Pretax Margin % only.
Vivani Medical (NAS:VANI) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Vivani Medical Pretax Margin % Related Terms
Vivani Medical Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Vivani Medical's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VANI vs BDTX, VTVT, TLSA: Pretax Margin % Comparison
For the Biotechnology subindustry, Vivani Medical's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivani Medical Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivani Medical's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Vivani Medical's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivani Medical (VANI) has a Pretax Margin % of % as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Vivani Medical and its competitors. According to the industry distribution chart, Vivani Medical ranks #999999 out of 948 companies in the Biotechnology industry.
Is Vivani Medical's Pretax Margin % too high?
Vivani Medical's current Pretax Margin % is %. Based on the distribution chart, Vivani Medical ranks #999999 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vivani Medical has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Vivani Medical's Pretax Margin % compare to BDTX and VTVT?
According to the Biotechnology industry distribution chart, Vivani Medical ranks #999999 out of 948 companies for Pretax Margin %. This places Vivani Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Vivani Medical and its competitors. Vivani Medical's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivani Medical stock overvalued right now?
Vivani Medical (VANI) has a current Pretax Margin % of %. The current Pretax Margin % is %. Vivani Medical's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Vivani Medical (VANI), the current Pretax Margin % is % as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
33GF Score
Get the complete analysis for VANI
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VANI has been successfully added to your 
